| Predicate |
Object |
| contentType |
Journal Article|Review |
| endingPage |
800 |
| issn |
1520-9156
1557-8593 |
| issueIdentifier |
5 |
| pageRange |
797-800 |
| publicationName |
Diabetes Technology & Therapeutics |
| startingPage |
797 |
| bibliographicCitation |
Aubry W. Reimbursement and coverage implications for CGM. Diabetes Technol Ther. 2005 Oct;7(5):797–800. doi: 10.1089/dia.2005.7.797. PMID: 16241886. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2387beead3007f18c6bfb2dc63c24a30 |
| date |
200510 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/16241886
https://doi.org/10.1089/dia.2005.7.797 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21552
https://portal.issn.org/resource/ISSN/1557-8593
https://portal.issn.org/resource/ISSN/1520-9156 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Reimbursement and Coverage Implications for CGM |
| discusses |
http://id.nlm.nih.gov/mesh/M0002696 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D015190Q000191
http://id.nlm.nih.gov/mesh/D012051Q000191
http://id.nlm.nih.gov/mesh/D003920Q000097
http://id.nlm.nih.gov/mesh/D001786Q000032 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D014481
http://id.nlm.nih.gov/mesh/D007348Q000191
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D015190Q000295
http://id.nlm.nih.gov/mesh/D006278Q000191
http://id.nlm.nih.gov/mesh/D015190Q000379
http://id.nlm.nih.gov/mesh/D003920Q000191 |